Straits Times Index
3,110.73 0.00 (0.00%) Nikkei
32,826.85 +518.99 (+1.61%) Hang Seng
16,334.37 -11.53 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
43,436.52 -325.16 (-0.74%) CMC Crypto 200
897.24 +0.53 (+0.06%)
Repare Therapeutics Inc. (RPTX)
After hours:
| Previous close | 5.75 |
| Open | 5.71 |
| Bid | 6.02 x 1000 |
| Ask | 6.69 x 800 |
| Day's range | 5.50 - 6.53 |
| 52-week range | 3.08 - 16.42 |
| Volume | |
| Avg. volume | 349,390 |
| Market cap | 267.524M |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.31 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.50 |
ZacksRepare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
- Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
CAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.
- Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass. & MONTREAL, November 09, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
